FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 338:867-873 March 26, 1998 Number 13 Next

Abstract PDF Editorial by Imura, H. Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

ABSTRACT

Background Combination therapy is logical for patients with non-insulin-dependent (type II) diabetes mellitus, because they often have poor responses to single-drug therapy. We studied the efficacy and physiologic effects of metformin and troglitazone alone and in combination in patients with type II diabetes.

Methods We randomly assigned 29 patients to receive either metformin or troglitazone for three months, after which they were given both drugs for another three months. Plasma glucose concentrations during fasting and postprandially and glycosylated hemoglobin values were measured periodically during both treatments. Endogenous glucose production and peripheral glucose disposal were measured at base line and after three and six months.

Results During metformin therapy, fasting and postprandial plasma glucose concentrations decreased by 20 percent (58 mg per deciliter [3.2 mmol per liter], P<0.001) and 25 percent (87 mg per deciliter [4.8 mmol per liter], P<0.001), respectively. The corresponding decreases during troglitazone therapy were 20 percent (54 mg per deciliter [2.9 mmol per liter], P = 0.01) and 25 percent (83 mg per deciliter [4.6 mmol per liter], P<0.001). Endogenous glucose production decreased during metformin therapy by a mean of 19 percent (P = 0.001), whereas it was unchanged by troglitazone therapy (P = 0.04 for the comparison between groups). The mean rate of glucose disposal increased by 54 percent during troglitazone therapy (P = 0.006) and 13 percent during metformin therapy (P = 0.03 for the comparison within the group and between groups). In combination, metformin and troglitazone further lowered fasting and postprandial plasma glucose concentrations by 18 percent (41 mg per deciliter [2.3 mmol per liter], P = 0.001) and 21 percent (54 mg per deciliter [3.0 mmol per liter], P<0.001), respectively, and the mean glycosylated hemoglobin value decreased 1.2 percentage points.

Conclusions Metformin and troglitazone have equal and additive beneficial effects on glycemic control in patients with type II diabetes. Metformin acts primarily by decreasing endogenous glucose production, and troglitazone by increasing the rate of peripheral glucose disposal.

Until recently in the United States, the only oral drugs available for patients with type II diabetes were sulfonylureas. These increase insulin secretion,² but they often lead to weight gain and may cause hypoglycemia. Recently, metformin became available. Its exact mechanisms of action are poorly understood, but they include suppression of endogenous glucose output³ and increased peripheral insulin sensitivity.⁴ In patients with diabetes, metformin lowers plasma glucose concentrations both alone^5,6 and in combination with a sulfonylurea,^6,7,8 while simultaneously decreasing plasma insulin concentrations. A third category of drug, -glucosidase inhibitors, decreases postprandial plasma glucose concentrations by delaying the absorption of carbohydrates.⁹ Troglitazone, the drug that has become available most recently, acts by increasing overall insulin sensitivity,¹⁰ with evidence of effects in both the liver,^11,12 the primary glucose-producing organ, and skeletal muscle,^13,14 the main site of glucose disposal. Troglitazone is effective both when given alone^15,16,17 and when given in combination with either a sulfonylurea^18,19 or insulin.²⁰ Given that metformin and troglitazone may have different metabolic actions, both with the theoretical advantage of reducing hyperglycemia without increasing insulin secretion, they are attractive prospects for combination therapy in patients with type II diabetes.

In this study, we evaluated the efficacy and physiologic effects of these two drugs during three months of monotherapy in a group of patients with type II diabetes and then during three months of combination therapy.

Methods

Study Subjects

We studied 29 patients with type II diabetes, as defined by the National Diabetes Data Group,²¹ who had a glycosylated hemoglobin value above the upper limit of normal and a plasma C-peptide concentration of at least 1.5 ng per milliliter (0.50 nmol per liter) while receiving dietary therapy or treatment with a sulfonylurea. Patients were excluded if they had abnormal renal or hepatic function or had had a recent atherosclerotic event. Fifteen patients (8 women and 7 men) were randomly assigned to receive metformin for three months, and 14 (8 women and 6 men) to receive troglitazone for three months. They then were treated with both drugs for an additional three months. Both the patients and the investigators were aware of the treatment. One patient assigned to receive troglitazone withdrew from the study after two weeks because of persistent hyperglycemia (plasma glucose concentrations, >350 mg per deciliter [19.4 mmol per liter]). One patient in each treatment group elected not to continue into the combination phase. Finally, two patients assigned to receive troglitazone completed the monotherapy period but not the period of combination therapy, because of intervening illnesses. The protocol was approved by the human-investigation committee of Yale University, and all the patients gave informed consent.

Study Design

            Monotherapy: Months 0 to 3

After a two-week washout period during which any previous drug therapy was discontinued, the patients received either 1000 mg of metformin twice daily orally or 400 mg of troglitazone once daily orally for three months. Plasma glucose, glycosylated hemoglobin, and routine hematologic and chemical values were measured at base line and monthly thereafter. At base line and month 3, the patients underwent an eight-hour mixed-meal tolerance test and a hyperinsulinemic–euglycemic clamp study²² with [6,6-²H]glucose to measure endogenous glucose production and glucose disposal rate.

            Combination Therapy: Months 4 to 6

After the initial three-month period, the patients were invited to continue therapy for a second three months, during which they took both the original drug and the other drug in combination. The patients were again followed monthly as described above, and at the end of the study period they underwent a final mixed-meal tolerance test and hyperinsulinemic–euglycemic clamp study. During the course of the study, the patients were prescribed a diet designed to maintain base-line body weight, with a composition of 50 percent carbohydrate, 34 percent fat, and 16 percent protein.

Meal-Tolerance Test

At approximately 7 a.m., with the patients in bed after a 12-hour fast, an intravenous catheter was inserted into an antecubital vein for blood sampling. At 8 a.m., the patients drank a liquid formula breakfast (Sustacal-HC) containing 33 percent of their total daily caloric intake, followed four hours later by an identical liquid lunch. Blood samples were drawn before the breakfast and then hourly for eight hours for measurements of plasma glucose, insulin, and C peptide. After completing the test, the patients received an evening meal and then fasted until the end of the clamp study, which was performed the next day. The mean of all plasma glucose values after the first test was taken as the postprandial value.

Hyperinsulinemic–Euglycemic Clamp Study

Beginning at 6 a.m., a primed (corrected for ambient fasting plasma glucose concentration) [6,6 -²H]glucose solution (2 mg per square meter of body-surface area per minute) was infused into the antecubital vein continuously for four hours. During the third hour, a retrograde cannula was inserted into a warmed vein of the contralateral hand for sampling of arterialized venous blood. Blood samples were drawn at 10-minute intervals during the final 40 minutes of the 4-hour basal period for the measurement of plasma glucose, insulin, and [²H]glucose. Then, a two-step priming dose of insulin was administered for 10 minutes (480 mU per square meter per minute for 5 minutes, followed by 240 mU per square meter per minute for 5 minutes), followed by a continuous infusion of insulin (120 mU per square meter per minute) for a total of 5 hours. The plasma glucose concentration was allowed to fall to 100 mg per deciliter (5.6 mmol per liter) and then maintained at that concentration by the administration of glucose (20 g of dextrose per 100 ml enriched to approximately 2.5 percent with [6,6 -²H]glucose). The basal isotope infusion was stopped when the exogenous glucose infusion was started. During the final hour of the clamp study, additional blood samples were drawn at 10-minute intervals for the measurement of plasma insulin and steady-state glucose isotope enrichment.

Substrate and Hormone Measurements

Plasma samples were shipped frozen to Corning Nichols Institute for chemical analysis. Plasma insulin was determined by radioimmunoassay, with an interassay coefficient of variation of 12.3 percent and an intraassay coefficient of variation of 7.4 percent. Plasma C peptide was also measured by radioimmunoassay, with an interassay coefficient of variation of 12.0 percent and an intraassay coefficient of variation of 6.5 percent. Glycosylated hemoglobin was measured by high-performance liquid chromatography (Bio-Rad), with a normal reference range of 4.5 to 5.9 percent; the assay was linear up to a value of 14 percent. Plasma glucose was measured at the bedside with a Beckman glucose analyzer.

Gas chromatography–mass spectrometry of the [6,6 -²H]glucose concentration in plasma was carried out at the Yale Stable Isotope Core Facility, with the pentaacetate derivative of glucose as described previously.²³ Basal endogenous glucose production was calculated with the following equation:

Basal endogenous glucose production = (f/BSA)x([enrichment_inf/enrichment_plasma]-1),

where f is the basal [6,6 -²H]glucose infusate rate (in milligrams per minute), BSA is the body-surface area (in square meters), enrichment_inf is the percent enrichment of [6,6-²H]glucose infusate, and enrichment_plasma is the percentage of basal plasma [6,6-²H]- glucose enrichment. The glucose disposal rate during clamping was calculated with the following equation:

Glucose disposal rate = cEGP+GIR,

where GIR is the mean rate of infusion of exogenous glucose from minutes 260 to 300 of the clamping period (in milligrams per square meter per minute), and cEGP is endogenous glucose production during clamping, calculated as follows:

Endogenous glucose production during clamping = GIR x([enrichment_inf/enrichment_plasma]-1),

where enrichment_inf is the percent [6,6-²H]glucose enrichment of infusate, and enrichment_plasma is the steady-state percentage of plasma [6,6-²H]glucose enrichment during clamping.

Statistical Analysis

Descriptive and inferential statistical analyses were performed with Systat, version 5.2.1. The actual results at each time were compared with repeated-measures analysis of variance. All statistical tests were two-sided.

Results

Characteristics of the Patients

The patients in the two groups were evenly matched with respect to age; body-mass index; fasting plasma glucose, insulin, and C-peptide concentrations; and glycosylated hemoglobin values (Table 1).

View this table: [in this window] [in a new window]   Table 1. Base-Line Characteristics of Patients with Type II Diabetes Mellitus Who Completed the Three-Month Monotherapy Phase of the Study.

 
Monotherapy

At three months, metformin and troglitazone lowered the mean fasting plasma glucose concentration by 58 mg per deciliter (3.2 mmol per liter) (P<0.001) and 54 mg per deciliter (3.0 mmol per liter) (P = 0.01), respectively, a decrease of 20 percent in both groups (Figure 1A). The glycosylated hemoglobin values did not change significantly in either group from the values obtained before the two-week period of washout from former therapy. During the meal-tolerance test, the mean postprandial plasma glucose concentration decreased by 87 mg per deciliter (4.8 mmol per liter) in the metformin group (P<0.001) and by 83 mg per deciliter (4.6 mmol per liter) in the troglitazone group (P<0.001), a decrease of 25 percent in both groups (Figure 1B). The mean fasting and postprandial plasma insulin and C-peptide concentrations decreased slightly but not significantly in both groups.

View larger version (10K): [in this window] [in a new window]   Figure 1. Mean (±SE) Changes in Fasting Plasma Glucose Concentrations (Panel A) and Postprandial Plasma Glucose Concentrations (Panel B) during Therapy with Metformin or Troglitazone for Three Months Followed by Combined Therapy with Metformin and Troglitazone for Three Months. The postprandial plasma glucose values are the means of eight hourly measurements made during the meal-tolerance test. To convert values for glucose to millimoles per liter, multiply by 0.056.

 
After three months of metformin therapy, mean endogenous glucose production decreased by 19 percent, from 108 to 87 mg per square meter per minute (6.0 to 4.8 mmol per square meter per minute, P = 0.001). In contrast, there was no significant change (-3 percent) in the troglitazone group (P = 0.04). The mean glucose-disposal rate increased in the troglitazone group by 54 percent, from 172 to 265 mg per square meter per minute (9.5 to 14.7 mmol per square meter per minute, P = 0.006). The increase with metformin therapy was comparatively less (13 percent; from 240 to 272 mg per square meter per minute [13.3 to 15.1 mmol per square meter per minute]; P = 0.03).

When the data were analyzed according to the mean percent changes in these values within subjects, endogenous glucose production decreased by a mean of 18 percent after three months of metformin therapy but was not significantly changed (-0.1 percent) by troglitazone therapy (Figure 2). The mean increase in the glucose-disposal rate within subjects was 97 percent in the troglitazone group and 27 percent in the metformin group (Figure 2). The changes in these results were also significantly different between the groups (P = 0.04 for the change in endogenous glucose production, and P = 0.03 for change in glucose disposal).

View larger version (8K): [in this window] [in a new window]   Figure 2. Mean (±SE) Percent Changes within Subjects in Endogenous Glucose Production and the Glucose Disposal Rate under Hyperinsulinemic-Clamp Conditions after Three Months of Therapy with Metformin or Troglitazone. NS denotes not significant.

 
Combination Therapy

During combination therapy, the mean fasting plasma glucose concentration decreased by an additional 41 mg per deciliter (2.3 mmol per liter) (P =0.001), a reduction of 18 percent, between three and six months (Figure 1A). The total mean decrease in fasting plasma glucose concentration in all patients during the six-month treatment period was 98 mg per deciliter (5.4 mmol per liter) (P = 0.001), a 35 percent reduction. During combination therapy the mean postprandial plasma glucose concentration decreased an additional 54 mg per deciliter (P<0.001), a reduction of 21 percent (Figure 1B). During the entire six-month study period, the mean postprandial plasma glucose concentration decreased by 140 mg per deciliter (7.8 mmol per liter) (P< 0.001), a 41 percent reduction. The mean glycosylated hemoglobin value also decreased during the three months of combination therapy, with a mean absolute fall of 1.2 percent from base line (P<0.001) (Figure 3). The mean fasting and postprandial plasma insulin and C-peptide concentrations were lower at six months than at base line, although the changes were small and not statistically significant.

View larger version (4K): [in this window] [in a new window]   Figure 3. Mean (±SE) Changes in Glycosylated Hemoglobin Values during Therapy with Metformin or Troglitazone for Three Months Followed by Combined Therapy with Metformin and Troglitazone for Three Months.

 
The addition of troglitazone to metformin resulted in no further decrease in basal endogenous glucose production. At six months in this group, mean endogenous glucose production was 90 mg per square meter per minute (5.0 mmol per square meter per minute), representing a decrease of 17 percent from base line (P = 0.002) and one not significantly different from the 19 percent decrease after three months of metformin alone. Similarly, in the group given metformin in addition to troglitazone, there was no decrease in endogenous glucose production at six months (92 mg per square meter per minute [5.1 mmol per square meter per minute]) as compared with base line (92 mg per square meter per minute) or after three months of troglitazone alone (89 mg per square meter per minute [4.9 mmol per square meter per minute]).

Adding troglitazone to metformin significantly increased the rate of glucose disposal to 337 mg per square meter per minute (18.7 mmol per square meter per minute), a mean increase of 24 percent over the three-month value (P = 0.04). In contradistinction, when metformin was added to troglitazone, the rate of glucose disposal increased to 304 mg per square meter per minute (16.9 mmol per square meter per minute), a mean increase of only 15 percent from three months (P = 0.30). The mean increase in the rate of glucose disposal between base line and six months was 40 percent (P<0.001) in the patients who received metformin first, with troglitazone added for the second three months, and it was 77 percent (P<0.001) in those initially treated with troglitazone, with metformin added for the second three months.

Body Weight and Adverse Events

There were no significant changes in body weight during either monotherapy or combination therapy. Intermittent diarrhea developed in one patient soon after metformin was added to troglitazone. She subsequently withdrew from the study. No other adverse events were ascribed to either monotherapy or combination therapy. The mean plasma lactate concentration was normal at all times in both groups, and no patient had any abnormalities on liver-function tests during the study.

Discussion

In this small group of patients with moderate type II diabetes, metformin and troglitazone had nearly identical efficacy in reducing plasma glucose concentrations. Their mechanisms of action, however, differed. Metformin primarily lowered endogenous glucose production, presumably at the level of the liver, whereas troglitazone increased insulin-mediated peripheral glucose disposal, which occurs predominantly in skeletal muscle. Peripheral glucose disposal was also increased by metformin, but the increase was less than one quarter of that associated with troglitazone. Whereas all the glucose-lowering effect of troglitazone at this dosage may be attributed to this peripheral effect, the action of metformin is more difficult to categorize. The effect of metformin on endogenous glucose production appears to be primary and substantial, with the 19 percent reduction translating to a correction of more than two thirds of the increase described in patients with type II diabetes.^24,25 The beneficial effect of metformin on glucose disposal, on the other hand, is in the same range as that which occurs in patients treated with sulfonylurea drugs.^26,27 Whether this is a direct effect of metformin or due to an overall decrease in glucose toxicity is not known.²⁸

The lack of effect of troglitazone at this dose on endogenous glucose production is in contrast to findings by others,^10,12,13 but is in agreement with the results of a recently reported large, multicenter study.¹⁴ At higher doses (600 mg per day), troglitazone therapy does result in small decreases in hepatic glucose production.¹⁴

Although both drugs alone resulted in improved glycemic profiles, the mean fasting plasma glucose concentrations remained high in both groups at three months. In combination, these drugs further reduced both fasting and postprandial plasma glucose concentrations. The addition of troglitazone to metformin resulted in a significant further increase in peripheral glucose disposal. The small, insignificant increase in glucose disposal when metformin was added to troglitazone suggests that the peripheral action of metformin is minimal. By six months, peripheral glucose disposal had increased in both groups, but the increase was greater among the patients who were initially given troglitazone. This may reflect a delayed effect of troglitazone,²⁹ since the group with the greater increase had received troglitazone for a full six months.

When troglitazone was added to metformin, there was no further decrease in endogenous glucose production, in keeping with our finding that troglitazone alone had no significant effect on this variable. However, the lack of further lowering of endogenous glucose production when metformin was added to troglitazone is more difficult to explain, particularly because these patients had a significant improvement in glycemic control during combined treatment.

In conclusion, metformin and troglitazone have different mechanisms of action, yet are equally effective in lowering plasma glucose concentrations in patients with type II diabetes. Combination metformin and troglitazone therapy results in further improvement in glucose control, without stimulation of insulin secretion and with reversal of the two principal pathophysiologic abnormalities in this disorder.

Supported in part by grants from the Public Health Service (RO1-DK49230, MO1-RR00125) and Warner-Lambert. Drs. Inzucchi and Shulman serve as consultants to Parke-Davis (Warner-Lambert). Presented in abstract form at the Annual Scientific Sessions of the American Diabetes Association, Boston, June 21–24, 1997.

We are indebted to David Silver for statistical guidance and to the nursing staff of the Yale–New Haven Hospital General Clinical Research Center for their skilled assistance in carrying out the metabolic studies.

Source Information

From the Section of Endocrinology, Yale University School of Medicine (S.E.I., D.G.M., G.R.S., S.L.P., F.S.R., V.W., G.I.S.), and the Howard Hughes Medical Institute (G.I.S.), both in New Haven, Conn.

Address reprint requests to Dr. Inzucchi at the Section of Endocrinology, TMP 5, Yale University School of Medicine, Box 208020, New Haven, CT 06520.

References

1. DeFronzo RA. The triumvirate: -cell, muscle, liver: a collusion responsible for NIDDM. Diabetes 1988;37:667-687. [Medline]
2. Ashcroft FM. Mechanisms of the glycaemic effects of sulfonylureas. Horm Metab Res 1996;28:456-463. [Medline]
3. Stumvoll M, Nurjhan N, Perriello G, Dailey G, Gerich JE. Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N Engl J Med 1995;333:550-554. [Free Full Text]
4. Fery F, Plat L, Balasse EO. Effects of metformin on the pathways of glucose utilization after oral glucose in non-insulin-dependent diabetes mellitus patients. Metabolism 1997;46:227-233. [CrossRef][Medline]
5. Dornan TL, Heller SR, Peck GM, Tattersall RB. Double-blind evaluation of efficacy and tolerability of metformin in NIDDM. Diabetes Care 1991;14:342-344. [Abstract]
6. DeFronzo RA, Goodman AM, Multicenter Metformin Study Group. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 1995;333:541-549. [Free Full Text]
7. Haupt E, Knick B, Koschinsky T, Liebermeister H, Schneider J, Hirche H. Oral antidiabetic combination therapy with sulphonylureas and metformin. Diabetes Metab 1991;17:224-231. 
8. Hermann LS, Scherstén B, Bitzén P-O, Kjellström T, Lingärde F, Melander A. Therapeutic comparison of metformin and sulfonylurea, alone and in various combinations. Diabetes Care 1994;17:1100-1109. [Abstract]
9. Toeller M. Alpha-glucosidase inhibitors in diabetes: efficacy in NIDDM subjects. Eur J Clin Invest 1994;24:Suppl 3:31-35.
10. Suter SL, Nolan JJ, Wallace P, Gumbiner B, Olefsky JM. Metabolic effects of new oral hypoglycemic agent CS-045 in NIDDM subjects. Diabetes Care 1992;15:193-203. [Abstract]
11. O'Rourke CM, Davis JA, Saltiel AR, Cornicelli JA. Metabolic effects of troglitazone in the Goto-Kakizaki rat, a non-obese and normolipidemic rodent model of non-insulin-dependent diabetes mellitus. Metabolism 1997;46:192-198. [CrossRef][Medline]
12. Lee M-K, Miles PD, Khoursheed M, Gao K-M, Moossa AR, Olefsky JM. Metabolic effects of troglitazone on fructose-induced insulin resistance in the rat. Diabetes 1995;43:1435-1439. [Abstract]
13. Ciaraldi TP, Gilmore A, Olefsky JM, Goldberg M, Heidenreich KA. In vitro studies on the action of CS-045, a new antidiabetic agent. Metabolism 1990;39:1056-1062. [CrossRef][Medline]
14. Troglitazone Study Group. The metabolic effects of troglitazone in non-insulin dependent diabetes. Diabetes 1997;46:Suppl 1:149A-149A.abstract 
15. Kumar S, Boulton A, Beck-Nielsen H, et al. Troglitazone, an insulin action enhancer, improves metabolic control in NIDDM patients. Diabetologia 1996;39:701-709. [Medline]
16. Iwamoto Y, Kosaka K, Kuzuya T, Akanuma Y, Shigeta Y, Kaneko T. Effects of troglitazone: a new hypoglycemic agent in patients with NIDDM poorly controlled by diet therapy. Diabetes Care 1996;19:151-156. [Abstract]
17. Valiquette T, Huang S, Whitcomb R. Effects of troglitazone monotherapy in patients with NIDDM: a 6-month multicenter study. Diabetes 1997;46:Suppl 1:43A-43A.abstract 
18. Iwamoto I, Kosaka K, Kuzuya T, Akanuma Y, Shigeta Y, Kaneko T. Effect of combination therapy of troglitazone and sulphonylureas in patients with type II diabetes who were poorly controlled by sulphonylurea therapy alone. Diabet Med 1996;13:365-370. [CrossRef][Medline]
19. Ghazzi M, Radke-Mitchell L, Venable T, Troglitazone Study Group, Whitcomb R. Troglitazone improves glycemic control in patients with type II diabetes who are not optimally controlled on sulfonylurea. Diabetes 1997;46:Suppl 1:44A-44A.abstract 
20. Raskin P, Graveline JF. Efficacy of troglitazone in combination with insulin in NIDDM. Diabetes 1997;46:Suppl 1:44A-44A.abstract
21. National Diabetes Data Group. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 1979;28:1039-1057. [Medline]
22. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 1979;237:E214-E233. [Free Full Text]
23. Radioactive and stable isotope tracers in biomedicine. In: Wolfe R. Principles and practice of kinetic analysis. New York: Wiley–Liss, 1992:283-315.
24. Magnusson I, Rothman DL, Katz LD, Shulman RG, Shulman GI. Increased rate of gluconeogenesis in type II diabetes mellitus: a 13C nuclear magnetic resonance study. J Clin Invest 1992;90:1323-1327.
25. Chen YD, Swislocki AL, Jeng CY, Juang JH, Reaven GM. Effect of time on measurement of hepatic glucose production. J Clin Endocrinol Metab 1988;67:1084-1088. [Abstract]
26. Sheu WH, Jeng CY, Fuh MM, Chen YD, Reaven GM. Effect of glipizide treatment on response to an infused glucose load in patients with NIDDM. Diabetes Care 1995;18:1582-1587. [Abstract]
27. Vestergaard H, Weinreb JE, Rosen AS, et al. Sulfonylurea therapy improves glucose disposal without changing skeletal muscle GLUT4 levels in noninsulin-dependent diabetes mellitus subjects: a longitudinal study. J Clin Endocrinol Metab 1995;80:270-275. [Abstract]
28. Rossetti L, Smith D, Shulman GI, Papachristou D, DeFronzo RA. Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats. J Clin Invest 1987;79:1510-1515.
29. Saltiel AR, Olefsky JM. Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes 1996;45:1661-1669. [Abstract]

Abstract PDF Editorial by Imura, H. Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

This article has been cited by other articles:

• Schwalfenberg, G. (2008). Vitamin D and diabetes: Improvement of glycemic control with vitamin D3 repletion. cfp 54: 864-866 [Full Text]  
• Tan, B. K., Heutling, D., Chen, J., Farhatullah, S., Adya, R., Keay, S. D., Kennedy, C. R., Lehnert, H., Randeva, H. S. (2008). Metformin Decreases the Adipokine Vaspin in Overweight Women With Polycystic Ovary Syndrome Concomitant With Improvement in Insulin Sensitivity and a Decrease in Insulin Resistance. Diabetes 57: 1501-1507 [Abstract] [Full Text]  
• Ruan, X., Zheng, F., Guan, Y. (2008). PPARs and the kidney in metabolic syndrome. Am. J. Physiol. Renal Physiol. 294: F1032-F1047 [Abstract] [Full Text]  
• Promintzer, M., Krebs, M., Todoric, J., Luger, A., Bischof, M. G., Nowotny, P., Wagner, O., Esterbauer, H., Anderwald, C. (2007). Insulin Resistance Is Unrelated to Circulating Retinol Binding Protein and Protein C Inhibitor. J. Clin. Endocrinol. Metab. 92: 4306-4312 [Abstract] [Full Text]  
• Bloomgarden, Z. T. (2007). The Avandia Debate. Diabetes Care 30: 2401-2408 [Full Text]  
• Schwalfenberg, G. (2007). Not enough vitamin D: Health consequences for Canadians. cfp 53: 841-854 [Abstract] [Full Text]  
• Zinman, B., Hoogwerf, B. J., Duran Garcia, S., Milton, D. R., Giaconia, J. M., Kim, D. D., Trautmann, M. E., Brodows, R. G. (2007). The Effect of Adding Exenatide to a Thiazolidinedione in Suboptimally Controlled Type 2 Diabetes: A Randomized Trial. ANN INTERN MED 146: 477-485 [Abstract] [Full Text]  
• Brehm, A., Thomaseth, K., Bernroider, E., Nowotny, P., Waldhausl, W., Pacini, G., Roden, M. (2006). The Role of Endocrine Counterregulation for Estimating Insulin Sensitivity from Intravenous Glucose Tolerance Tests. J. Clin. Endocrinol. Metab. 91: 2272-2278 [Abstract] [Full Text]  
• Iglesias, P., Diez, J. J (2006). Peroxisome proliferator-activated receptor gamma agonists in renal disease.. Eur J Endocrinol 154: 613-621 [Abstract] [Full Text]  
• Lessard, S. J., Chen, Z.-P., Watt, M. J., Hashem, M., Reid, J. J., Febbraio, M. A., Kemp, B. E., Hawley, J. A. (2006). Chronic rosiglitazone treatment restores AMPK{alpha}2 activity in insulin-resistant rat skeletal muscle. Am. J. Physiol. Endocrinol. Metab. 290: E251-E257 [Abstract] [Full Text]  
• Bernroider, E., Brehm, A., Krssak, M., Anderwald, C., Trajanoski, Z., Cline, G., Shulman, G. I., Roden, M. (2005). The Role of Intramyocellular Lipids during Hypoglycemia in Patients with Intensively Treated Type 1 Diabetes. J. Clin. Endocrinol. Metab. 90: 5559-5565 [Abstract] [Full Text]  
• Inzucchi, S. E., Masoudi, F. A., Wang, Y., Kosiborod, M., Foody, J. M., Setaro, J. F., Havranek, E. P., Krumholz, H. M. (2005). Insulin-Sensitizing Antihyperglycemic Drugs and Mortality After Acute Myocardial Infarction: Insights from the National Heart Care Project. Diabetes Care 28: 1680-1689 [Abstract] [Full Text]  
• Karlsson, H. K.R., Hallsten, K., Bjornholm, M., Tsuchida, H., Chibalin, A. V., Virtanen, K. A., Heinonen, O. J., Lonnqvist, F., Nuutila, P., Zierath, J. R. (2005). Effects of Metformin and Rosiglitazone Treatment on Insulin Signaling and Glucose Uptake in Patients With Newly Diagnosed Type 2 Diabetes: A Randomized Controlled Study. Diabetes 54: 1459-1467 [Abstract] [Full Text]  
• Kimmel, B., Inzucchi, S. E. (2005). Oral Agents for Type 2 Diabetes: An Update. Clin. Diabetes 23: 64-76 [Abstract] [Full Text]  
• Cheng, A. Y.Y., Fantus, I. G. (2005). Oral antihyperglycemic therapy for type 2 diabetes mellitus. CMAJ 172: 213-226 [Abstract] [Full Text]  
• Miyazaki, Y., De Filippis, E., Bajaj, M., Wajcberg, E., Glass, L., Triplitt, C., Cersosimo, E., Mandarino, L. J, Defronzo, R. A (2005). Predictors of improved glycaemic control with rosiglitazone therapy in type 2 diabetic patients: a practical approach for the primary care physician. British Journal of Diabetes & Vascular Disease 5: 28-35 [Abstract]  
• Knouff, C., Auwerx, J. (2004). Peroxisome Proliferator-Activated Receptor-{gamma} Calls for Activation in Moderation: Lessons from Genetics and Pharmacology. Endocr. Rev. 25: 899-918 [Abstract] [Full Text]  
• Cefalu, W. T., Hu, F. B. (2004). Role of Chromium in Human Health and in Diabetes. Diabetes Care 27: 2741-2751 [Full Text]  
• Guan, Y. (2004). Peroxisome Proliferator-Activated Receptor Family and Its Relationship to Renal Complications of the Metabolic Syndrome. J. Am. Soc. Nephrol. 15: 2801-2815 [Abstract] [Full Text]  
• Bouche, C., Serdy, S., Kahn, C. R., Goldfine, A. B. (2004). The Cellular Fate of Glucose and Its Relevance in Type 2 Diabetes. Endocr. Rev. 25: 807-830 [Abstract] [Full Text]  
• Zander, M., Christiansen, A., Madsbad, S., Juul Holst, J. (2004). Additive Effects of Glucagon-Like Peptide 1 and Pioglitazone in Patients With Type 2 Diabetes. Diabetes Care 27: 1910-1914 [Abstract] [Full Text]  
• Tiikkainen, M., Hakkinen, A.-M., Korsheninnikova, E., Nyman, T., Makimattila, S., Yki-Jarvinen, H. (2004). Effects of Rosiglitazone and Metformin on Liver Fat Content, Hepatic Insulin Resistance, Insulin Clearance, and Gene Expression in Adipose Tissue in Patients With Type 2 Diabetes. Diabetes 53: 2169-2176 [Abstract] [Full Text]  
• Kunhiraman, B., Itoua-Nganongo, W., Fonseca, V. (2004). Avandamet. British Journal of Diabetes & Vascular Disease 4: 268-271 [Abstract]  
• Strowig, S. M., Aviles-Santa, M. L., Raskin, P. (2004). Improved Glycemic Control Without Weight Gain Using Triple Therapy in Type 2 Diabetes. Diabetes Care 27: 1577-1583 [Abstract] [Full Text]  
• Natali, A., Baldeweg, S., Toschi, E., Capaldo, B., Barbaro, D., Gastaldelli, A., Yudkin, J. S., Ferrannini, E. (2004). Vascular Effects of Improving Metabolic Control With Metformin or Rosiglitazone in Type 2 Diabetes. Diabetes Care 27: 1349-1357 [Abstract] [Full Text]  
• Tonelli, J., Li, W., Kishore, P., Pajvani, U. B., Kwon, E., Weaver, C., Scherer, P. E., Hawkins, M. (2004). Mechanisms of Early Insulin-Sensitizing Effects of Thiazolidinediones in Type 2 Diabetes. Diabetes 53: 1621-1629 [Abstract] [Full Text]  
• Chiu, K. C, Chu, A., Go, V. L. W, Saad, M. F (2004). Hypovitaminosis D is associated with insulin resistance and {beta} cell dysfunction. Am. J. Clin. Nutr. 79: 820-825 [Abstract] [Full Text]  
• Brunmair, B., Staniek, K., Gras, F., Scharf, N., Althaym, A., Clara, R., Roden, M., Gnaiger, E., Nohl, H., Waldhausl, W., Furnsinn, C. (2004). Thiazolidinediones, Like Metformin, Inhibit Respiratory Complex I: A Common Mechanism Contributing to Their Antidiabetic Actions?. Diabetes 53: 1052-1059 [Abstract] [Full Text]  
• Hein, M. D. (2004). Management of Hyperglycemia in the Hospitalized Podiatric Medical Patient. J. Am. Podiatr. Med. Assoc. 94: 135-148 [Abstract] [Full Text]  
• Fonseca, V., Desouza, C., Asnani, S., Jialal, I. (2004). Nontraditional Risk Factors for Cardiovascular Disease in Diabetes. Endocr. Rev. 25: 153-175 [Abstract] [Full Text]  
• Bays, H., Mandarino, L., DeFronzo, R. A. (2004). Role of the Adipocyte, Free Fatty Acids, and Ectopic Fat in Pathogenesis of Type 2 Diabetes Mellitus: Peroxisomal Proliferator-Activated Receptor Agonists Provide a Rational Therapeutic Approach. J. Clin. Endocrinol. Metab. 89: 463-478 [Full Text]  
• Koski, R. R. (2004). Oral Antidiabetic Agents: A Comparative Review. Journal of Pharmacy Practice 17: 39-48 [Abstract]  
• Poulsen, M. K., Henriksen, J. E., Hother-Nielsen, O., Beck-Nielsen, H. (2003). The Combined Effect of Triple Therapy With Rosiglitazone, Metformin, and Insulin Aspart in Type 2 Diabetic Patients. Diabetes Care 26: 3273-3279 [Abstract] [Full Text]  
• Salpeter, S. R., Greyber, E., Pasternak, G. A., Salpeter, E. E. (2003). Risk of Fatal and Nonfatal Lactic Acidosis With Metformin Use in Type 2 Diabetes Mellitus: Systematic Review and Meta-analysis. Arch Intern Med 163: 2594-2602 [Abstract] [Full Text]  
• Hurst, R. T., Lee, R. W. (2003). Increased Incidence of Coronary Atherosclerosis in Type 2 Diabetes Mellitus: Mechanisms and Management. ANN INTERN MED 139: 824-834 [Abstract] [Full Text]  
• Kunert, O., Stingl, H., Rosian, E., Krssak, M., Bernroider, E., Seebacher, W., Zangger, K., Staehr, P., Chandramouli, V., Landau, B.R., Nowotny, P., Waldhausl, W., Haslinger, E., Roden, M. (2003). Measurement of Fractional Whole-Body Gluconeogenesis in Humans From Blood Samples Using 2H Nuclear Magnetic Resonance Spectroscopy. Diabetes 52: 2475-2482 [Abstract] [Full Text]  
• Gavrilova, O., Haluzik, M., Matsusue, K., Cutson, J. J., Johnson, L., Dietz, K. R., Nicol, C. J., Vinson, C., Gonzalez, F. J., Reitman, M. L. (2003). Liver Peroxisome Proliferator-activated Receptor {gamma} Contributes to Hepatic Steatosis, Triglyceride Clearance, and Regulation of Body Fat Mass. J. Biol. Chem. 278: 34268-34276 [Abstract] [Full Text]  
• Gerich, J. E. (2003). Clinical Significance, Pathogenesis, and Management of Postprandial Hyperglycemia. Arch Intern Med 163: 1306-1316 [Abstract] [Full Text]  
• Kernan, W. N., Inzucchi, S. E., Viscoli, C. M., Brass, L. M., Bravata, D. M., Shulman, G. I., McVeety, J. C., Horwitz, R. I. (2003). Pioglitazone Improves Insulin Sensitivity Among Nondiabetic Patients With a Recent Transient Ischemic Attack or Ischemic Stroke. Stroke 34: 1431-1436 [Abstract] [Full Text]  
• Leow, M. K. S., Addy, C. L., Mantzoros, C. S. (2003). Human Immunodeficiency Virus/Highly Active Antiretroviral Therapy-Associated Metabolic Syndrome: Clinical Presentation, Pathophysiology, and Therapeutic Strategies. J. Clin. Endocrinol. Metab. 88: 1961-1976 [Full Text]  
• Pavo, I., Jermendy, G., Varkonyi, T. T., Kerenyi, Z., Gyimesi, A., Shoustov, S., Shestakova, M., Herz, M., Johns, D., Schluchter, B. J., Festa, A., Tan, M. H. (2003). Effect of Pioglitazone Compared with Metformin on Glycemic Control and Indicators of Insulin Sensitivity in Recently Diagnosed Patients with Type 2 Diabetes. J. Clin. Endocrinol. Metab. 88: 1637-1645 [Abstract] [Full Text]  
• The Diabetes Prevention Program Research Group, (2003). Effects of Withdrawal From Metformin on the Development of Diabetes in the Diabetes Prevention Program. Diabetes Care 26: 977-980 [Abstract] [Full Text]  
• Bluher, M., Lubben, G., Paschke, R. (2003). Analysis of the Relationship Between the Pro12Ala Variant in the PPAR-{gamma}2 Gene and the Response Rate to Therapy With Pioglitazone in Patients With Type 2 Diabetes. Diabetes Care 26: 825-831 [Abstract] [Full Text]  
• Phillips, S. A., Ciaraldi, T. P., Kong, A. P.S., Bandukwala, R., Aroda, V., Carter, L., Baxi, S., Mudaliar, S. R., Henry, R. R. (2003). Modulation of Circulating and Adipose Tissue Adiponectin Levels by Antidiabetic Therapy. Diabetes 52: 667-674 [Abstract] [Full Text]  
• Evans, J. L., Goldfine, I. D., Maddux, B. A., Grodsky, G. M. (2003). Are Oxidative Stress-Activated Signaling Pathways Mediators of Insulin Resistance and {beta}-Cell Dysfunction?. Diabetes 52: 1-8 [Abstract] [Full Text]  
• Raji, A., Seely, E. W., Bekins, S. A., Williams, G. H., Simonson, D. C. (2003). Rosiglitazone Improves Insulin Sensitivity and Lowers Blood Pressure in Hypertensive Patients. Diabetes Care 26: 172-178 [Abstract] [Full Text]  
• Defronzo, R. A (2003). Impaired glucose tolerance: do pharmacological therapies correct the underlying metabolic disturbance?. British Journal of Diabetes & Vascular Disease 3: S24-S40 [Abstract]  
• Meyer, L., Bohme, P., Delbachian, I., Lehert, P., Cugnardey, N., Drouin, P., Guerci, B. (2002). The Benefits of Metformin Therapy During Continuous Subcutaneous Insulin Infusion Treatment of Type 1 Diabetic Patients. Diabetes Care 25: 2153-2158 [Abstract] [Full Text]  
• Hallsten, K., Virtanen, K. A., Lonnqvist, F., Sipila, H., Oksanen, A., Viljanen, T., Ronnemaa, T., Viikari, J., Knuuti, J., Nuutila, P. (2002). Rosiglitazone but Not Metformin Enhances Insulin- and Exercise-Stimulated Skeletal Muscle Glucose Uptake in Patients With Newly Diagnosed Type 2 Diabetes. Diabetes 51: 3479-3485 [Abstract] [Full Text]  
• Nathan, D. M. (2002). Initial Management of Glycemia in Type 2 Diabetes Mellitus. NEJM 347: 1342-1349 [Full Text]  
• Willi, S. M., Kennedy, A., Wallace, P., Ganaway, E., Rogers, N. L., Garvey, W. T. (2002). Troglitazone Antagonizes Metabolic Effects of Glucocorticoids in Humans: Effects on Glucose Tolerance, Insulin Sensitivity, Suppression of Free Fatty Acids, and Leptin. Diabetes 51: 2895-2902 [Abstract] [Full Text]  
• Anderwald, C., Bernroider, E., Krssak, M., Stingl, H., Brehm, A., Bischof, M. G., Nowotny, P., Roden, M., Waldhausl, W. (2002). Effects of Insulin Treatment in Type 2 Diabetic Patients on Intracellular Lipid Content in Liver and Skeletal Muscle. Diabetes 51: 3025-3032 [Abstract] [Full Text]  
• Kernan, W. N., Inzucchi, S. E., Viscoli, C. M., Brass, L. M., Bravata, D. M., Horwitz, R. I. (2002). Insulin resistance and risk for stroke. Neurology 59: 809-815 [Abstract] [Full Text]  
• Rosenstock, J., Shen, S. G., Gatlin, M. R., Foley, J. E. (2002). Combination Therapy With Nateglinide and a Thiazolidinedione Improves Glycemic Control in Type 2 Diabetes. Diabetes Care 25: 1529-1533 [Abstract] [Full Text]  
• Paniagua, J.A., Lopez-Miranda, J., Escribano, A., Berral, F.J., Marin, C., Bravo, D., Paz-Rojas, E., Gomez, P., Barcos, M., Moreno, J.A., Perez-Jimenez, F. (2002). Cerivastatin Improves Insulin Sensitivity and Insulin Secretion in Early-State Obese Type 2 Diabetes. Diabetes 51: 2596-2603 [Abstract] [Full Text]  
• Fryer, L. G. D., Parbu-Patel, A., Carling, D. (2002). The Anti-diabetic Drugs Rosiglitazone and Metformin Stimulate AMP-activated Protein Kinase through Distinct Signaling Pathways. J. Biol. Chem. 277: 25226-25232 [Abstract] [Full Text]  
• Kirpichnikov, D., McFarlane, S. I., Sowers, J. R. (2002). Metformin: An Update. ANN INTERN MED 137: 25-33 [Abstract] [Full Text]  
• Musi, N., Hirshman, M. F., Nygren, J., Svanfeldt, M., Bavenholm, P., Rooyackers, O., Zhou, G., Williamson, J. M., Ljunqvist, O., Efendic, S., Moller, D. E., Thorell, A., Goodyear, L. J. (2002). Metformin Increases AMP-Activated Protein Kinase Activity in Skeletal Muscle of Subjects With Type 2 Diabetes. Diabetes 51: 2074-2081 [Abstract] [Full Text]  
• Miyazaki, Y., Mahankali, A., Matsuda, M., Mahankali, S., Hardies, J., Cusi, K., Mandarino, L. J., DeFronzo, R. A. (2002). Effect of Pioglitazone on Abdominal Fat Distribution and Insulin Sensitivity in Type 2 Diabetic Patients. J. Clin. Endocrinol. Metab. 87: 2784-2791 [Abstract] [Full Text]  
• Forman, B. M. (2002). The Antidiabetic Agent LG100754 Sensitizes Cells to Low Concentrations of Peroxisome Proliferator-activated Receptor gamma Ligands. J. Biol. Chem. 277: 12503-12506 [Abstract] [Full Text]  
• Homburg, R. (2002). Should patients with polycystic ovarian syndrome be treated with metformin?: A note of cautious optimism. Hum Reprod 17: 853-856 [Abstract] [Full Text]  
• Miyazaki, Y., Matsuda, M., DeFronzo, R. A. (2002). Dose-Response Effect of Pioglitazone on Insulin Sensitivity and Insulin Secretion in Type 2 Diabetes. Diabetes Care 25: 517-523 [Abstract] [Full Text]  
• Chu, N. V., Kong, A. P. S., Kim, D. D., Armstrong, D., Baxi, S., Deutsch, R., Caulfield, M., Mudaliar, S. R., Reitz, R., Henry, R. R., Reaven, P. D. (2002). Differential Effects of Metformin and Troglitazone on Cardiovascular Risk Factors in Patients With Type 2 Diabetes. Diabetes Care 25: 542-549 [Abstract] [Full Text]  
• Krebs, M., Krssak, M., Bernroider, E., Anderwald, C., Brehm, A., Meyerspeer, M., Nowotny, P., Roth, E., Waldhausl, W., Roden, M. (2002). Mechanism of Amino Acid-Induced Skeletal Muscle Insulin Resistance in Humans. Diabetes 51: 599-605 [Abstract] [Full Text]  
• Mayerson, A. B., Hundal, R. S., Dufour, S., Lebon, V., Befroy, D., Cline, G. W., Enocksson, S., Inzucchi, S. E., Shulman, G. I., Petersen, K. F. (2002). The Effects of Rosiglitazone on Insulin Sensitivity, Lipolysis, and Hepatic and Skeletal Muscle Triglyceride Content in Patients With Type 2 Diabetes. Diabetes 51: 797-802 [Abstract] [Full Text]  
• Kim, Y.-B., Ciaraldi, T. P., Kong, A., Kim, D., Chu, N., Mohideen, P., Mudaliar, S., Henry, R. R., Kahn, B. B. (2002). Troglitazone but not Metformin Restores Insulin-Stimulated Phosphoinositide 3-Kinase Activity and Increases p110{beta} Protein Levels in Skeletal Muscle of Type 2 Diabetic Subjects. Diabetes 51: 443-448 [Abstract] [Full Text]  
• Inzucchi, S. E. (2002). Oral Antihyperglycemic Therapy for Type 2 Diabetes: Scientific Review. JAMA 287: 360-372 [Abstract] [Full Text]  
• Ciaraldi, T. P., Kong, A. P.S., Chu, N. V., Kim, D. D., Baxi, S., Loviscach, M., Plodkowski, R., Reitz, R., Caulfield, M., Mudaliar, S., Henry, R. R. (2002). Regulation of Glucose Transport and Insulin Signaling by Troglitazone or Metformin in Adipose Tissue of Type 2 Diabetic Subjects. Diabetes 51: 30-36 [Abstract] [Full Text]  
• Zhang, Z., Radziuk, J. (2001). Inverse relationship between peripheral insulin removal and action: studies with metformin. Am. J. Physiol. Endocrinol. Metab. 281: E1240-E1248 [Abstract] [Full Text]  
• Brunmair, B., Gras, F., Neschen, S., Roden, M., Wagner, L., Waldhausl, W., Furnsinn, C. (2001). Direct Thiazolidinedione Action on Isolated Rat Skeletal Muscle Fuel Handling Is Independent of Peroxisome Proliferator-Activated Receptor-{gamma}-Mediated Changes in Gene Expression. Diabetes 50: 2309-2315 [Abstract] [Full Text]  
• Vinik, A. I., Erbas, T., Park, T. S., Stansberry, K. B., Scanelli, J. A., Pittenger, G. L. (2001). Dermal Neurovascular Dysfunction in Type 2 Diabetes. Diabetes Care 24: 1468-1475 [Abstract] [Full Text]  
• Chiasson, J.-L., Naditch, L. (2001). The Synergistic Effect of Miglitol Plus Metformin Combination Therapy in the Treatment of Type 2 Diabetes. Diabetes Care 24: 989-994 [Abstract] [Full Text]  
• Krebs, M., Krssak, M., Nowotny, P., Weghuber, D., Gruber, S., Mlynarik, V., Bischof, M., Stingl, H., Fürnsinn, C., Waldhäusl, W., Roden, M. (2001). Free Fatty Acids Inhibit the Glucose-Stimulated Increase of Intramuscular Glucose-6-Phosphate Concentration in Humans. J. Clin. Endocrinol. Metab. 86: 2153-2160 [Abstract] [Full Text]  
• Baba, T., Shimada, K., Neugebauer, S., Yamada, D., Hashimoto, S., Watanabe, T. (2001). The Oral Insulin Sensitizer, Thiazolidinedione, Increases Plasma Vascular Endothelial Growth Factor in Type 2 Diabetic Patients. Diabetes Care 24: 953-954 [Full Text]  
• Yonemitsu, S., Nishimura, H., Shintani, M., Inoue, R., Yamamoto, Y., Masuzaki, H., Ogawa, Y., Hosoda, K., Inoue, G., Hayashi, T., Nakao, K. (2001). Troglitazone Induces GLUT4 Translocation in L6 Myotubes. Diabetes 50: 1093-1101 [Abstract] [Full Text]  
• Miyazaki, Y., Mahankali, A., Matsuda, M., Glass, L., Mahankali, S., Ferrannini, E., Cusi, K., Mandarino, L. J., DeFronzo, R. A. (2001). Improved Glycemic Control and Enhanced Insulin Sensitivity in Type 2 Diabetic Subjects Treated With Pioglitazone. Diabetes Care 24: 710-719 [Abstract] [Full Text]  
• Jakubowicz, D. J., Seppälä, M., Jakubowicz, S., Rodriguez-Armas, O., Rivas-Santiago, A., Koistinen, H., Koistinen, R., Nestler, J. E. (2001). Insulin Reduction with Metformin Increases Luteal Phase Serum Glycodelin and Insulin-Like Growth Factor-Binding Protein 1 Concentrations and Enhances Uterine Vascularity and Blood Flow in the Polycystic Ovary Syndrome. J. Clin. Endocrinol. Metab. 86: 1126-1133 [Abstract] [Full Text]  
• Matthaei, S., Stumvoll, M., Kellerer, M., Häring, H.-U. (2000). Pathophysiology and Pharmacological Treatment of Insulin Resistance. Endocr. Rev. 21: 585-618 [Abstract] [Full Text]  
• Takagi, T., Akasaka, T., Yamamuro, A., Honda, Y., Hozumi, T., Morioka, S., Yoshida, K. (2000). Troglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with non-insulin dependent diabetes mellitus: A serial intravascular ultrasound study. J Am Coll Cardiol 36: 1529-1535 [Abstract] [Full Text]  
• Russell, J. C., Ravel, D., Pégorier, J.-P., Delrat, P., Jochemsen, R., O'Brien, S. F., Kelly, S. E., Davidge, S. T., Brindley, D. N. (2000). Beneficial Insulin-Sensitizing and Vascular Effects of S15261 in the Insulin-Resistant JCR:LA-cp Rat. J. Pharmacol. Exp. Ther. 295: 753-760 [Abstract] [Full Text]  
• Arioglu, E., Duncan-Morin, J., Sebring, N., Rother, K. I., Gottlieb, N., Lieberman, J., Herion, D., Kleiner, D. E., Reynolds, J., Premkumar, A., Sumner, A. E., Hoofnagle, J., Reitman, M. L., Taylor, S. I. (2000). Efficacy and Safety of Troglitazone in the Treatment of Lipodystrophy Syndromes. ANN INTERN MED 133: 263-274 [Abstract] [Full Text]  
• Hoppener, J. W.M., Ahren, B., Lips, C. J.M. (2000). Islet Amyloid and Type 2 Diabetes Mellitus. NEJM 343: 411-419 [Full Text]  
• Deplewski, D., Rosenfield, R. L. (2000). Role of Hormones in Pilosebaceous Unit Development. Endocr. Rev. 21: 363-392 [Abstract] [Full Text]  
• Fonseca, V., Rosenstock, J., Patwardhan, R., Salzman, A. (2000). Effect of Metformin and Rosiglitazone Combination Therapy in Patients With Type 2 Diabetes Mellitus: A Randomized Controlled Trial. JAMA 283: 1695-1702 [Abstract] [Full Text]  
• Nordt, T. K., Peter, K., Bode, C., Sobel, B. E. (2000). Differential Regulation by Troglitazone of Plasminogen Activator Inhibitor Type 1 in Human Hepatic and Vascular Cells. J. Clin. Endocrinol. Metab. 85: 1563-1568 [Abstract] [Full Text]  
• Law, R. E., Goetze, S., Xi, X.-P., Jackson, S., Kawano, Y., Demer, L., Fishbein, M. C., Meehan, W. P., Hsueh, W. A. (2000). Expression and Function of PPAR{gamma} in Rat and Human Vascular Smooth Muscle Cells. Circulation 101: 1311-1318 [Abstract] [Full Text]  
• Zhu, P., Lu, L., Xu, Y., Schwartz, G. G. (2000). Troglitazone Improves Recovery of Left Ventricular Function After Regional Ischemia in Pigs. Circulation 101: 1165-1171 [Abstract] [Full Text]  
• Moghetti, P., Castello, R., Negri, C., Tosi, F., Perrone, F., Caputo, M., Zanolin, E., Muggeo, M. (2000). Metformin Effects on Clinical Features, Endocrine and Metabolic Profiles, and Insulin Sensitivity in Polycystic Ovary Syndrome: A Randomized, Double-Blind, Placebo-Controlled 6-Month Trial, followed by Open, Long-Term Clinical Evaluation. J. Clin. Endocrinol. Metab. 85: 139-146 [Abstract] [Full Text]  
• Katakam, P. V. G., Ujhelyi, M. R., Hoenig, M., Miller, A. W. (2000). Metformin Improves Vascular Function in Insulin-Resistant Rats. Hypertension 35: 108-112 [Abstract] [Full Text]  
• DeFronzo, R. A. (1999). Pharmacologic Therapy for Type 2 Diabetes Mellitus. ANN INTERN MED 131: 281-303 [Abstract] [Full Text]  
• Shepherd, P. R., Kahn, B. B. (1999). Glucose Transporters and Insulin Action -- Implications for Insulin Resistance and Diabetes Mellitus. NEJM 341: 248-257 [Full Text]  
• Nakajima, T., Iwasawa, K., Oonuma, H., Imuta, H., Hazama, H., Asano, M., Morita, T., Nakamura, F., Suzuki, J.-i., Suzuki, S., Kawakami, Y., Omata, M., Okuda, Y. (1999). Troglitazone Inhibits Voltage-Dependent Calcium Currents in Guinea Pig Cardiac Myocytes. Circulation 99: 2942-2950 [Abstract] [Full Text]  
• Mahler, R. J., Adler, M. L. (1999). Type 2 Diabetes Mellitus: Update on Diagnosis, Pathophysiology, and Treatment. J. Clin. Endocrinol. Metab. 84: 1165-1171 [Full Text]  
• Marx, N., Schonbeck, U., Lazar, M. A., Libby, P., Plutzky, J. (1998). Peroxisome Proliferator-Activated Receptor Gamma Activators Inhibit Gene Expression and Migration in Human Vascular Smooth Muscle Cells. Circ. Res. 83: 1097-1103 [Abstract] [Full Text]  
• Marx, N., Sukhova, G., Murphy, C., Libby, P., Plutzky, J. (1998). Macrophages in Human Atheroma Contain PPAR{gamma} : Differentiation-Dependent Peroxisomal Proliferator-ActivatedReceptor {gamma} (PPAR{gamma}) Expression and Reduction of MMP-9 Activitythrough PPAR{gamma} Activation in Mononuclear Phagocytes inVitro. Am. J. Pathol. 153: 17-23 [Abstract] [Full Text]  
• (1998). Troglitazone for Type 2 Diabetes. JWatch General 1998: 1-1 [Full Text]  
• Imura, H. (1998). A Novel Antidiabetic Drug, Troglitazone -- Reason for Hope and Concern. NEJM 338: 908-909 [Full Text]  
• Watkins, P. B., Whitcomb, R. W. (1998). Hepatic Dysfunction Associated with Troglitazone. NEJM 338: 916-917 [Full Text]  
• Jyothirmayi, G.N., Soni, B.J., Masurekar, M., Lyons, M., Regan, T.J. (1998). Effects of Metformin on Collagen Glycation and Diastolic Dysfunction in Diabetic Myocardium. J CARDIOVASC PHARMACOL THER 3: 319-326 [Abstract]